erlotinib hydrochloride has been researched along with osimertinib in 71 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (osimertinib) | Trials (osimertinib) | Recent Studies (post-2010) (osimertinib) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 1,315 | 134 | 1,282 |
| Protein | Taxonomy | erlotinib hydrochloride (IC50) | osimertinib (IC50) |
|---|---|---|---|
| Histone deacetylase 3 | Homo sapiens (human) | 1 | |
| Lysine-specific histone demethylase 1A | Homo sapiens (human) | 3.98 | |
| Epidermal growth factor receptor | Homo sapiens (human) | 0.1858 | |
| Receptor tyrosine-protein kinase erbB-2 | Homo sapiens (human) | 0.0274 | |
| Insulin receptor | Homo sapiens (human) | 0.912 | |
| Replicase polyprotein 1ab | Severe acute respiratory syndrome coronavirus 2 | 3.26 | |
| Receptor tyrosine-protein kinase erbB-3 | Homo sapiens (human) | 0.0268 | |
| von Hippel-Lindau disease tumor suppressor | Homo sapiens (human) | 0.002 | |
| Histone deacetylase 4 | Homo sapiens (human) | 1 | |
| Fatty-acid amide hydrolase 1 | Rattus norvegicus (Norway rat) | 0.0395 | |
| Epidermal growth factor receptor | Mus musculus (house mouse) | 0.081 | |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 0.57 | |
| Histone deacetylase 1 | Homo sapiens (human) | 1 | |
| Receptor tyrosine-protein kinase erbB-4 | Homo sapiens (human) | 0.033 | |
| Histone deacetylase 7 | Homo sapiens (human) | 1 | |
| Histone deacetylase 2 | Homo sapiens (human) | 1 | |
| Polyamine deacetylase HDAC10 | Homo sapiens (human) | 1 | |
| Histone deacetylase 11 | Homo sapiens (human) | 1 | |
| Histone deacetylase 8 | Homo sapiens (human) | 1 | |
| Histone deacetylase 6 | Homo sapiens (human) | 1 | |
| Histone deacetylase 9 | Homo sapiens (human) | 1 | |
| ALK tyrosine kinase receptor | Homo sapiens (human) | 0.177 | |
| Histone deacetylase 5 | Homo sapiens (human) | 1 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 35 (49.30) | 24.3611 |
| 2020's | 36 (50.70) | 2.80 |
| Authors | Studies |
|---|---|
| Gilligan, D; Pacey, S; Tan, CS | 1 |
| Dickson, JM; Flanagan, JU; McKeage, MJ; Patterson, AV; Silva, S; Smaill, JB; Squire, CJ; Yosaatmadja, Y | 1 |
| Baumgardner, M; Bryan, MC; Chen, Y; Eigenbrot, C; Fan, P; Gu, XH; Hanan, EJ; Heffron, TP; La, H; Malek, S; Purkey, HE; Schaefer, G; Schmidt, S; Sideris, S; Yen, I; Yu, C | 1 |
| Chen, M; Kanteti, R; Li, Y; Oh, YT; Owonikoko, TK; Ramalingam, SS; Riehm, J; Salgia, R; Shi, P; Sun, SY; Yao, W; Yue, P; Zhang, G | 1 |
| Pakkala, S; Ramalingam, SS | 1 |
| Jänne, PA; Saxon, JA; Sholl, LM | 1 |
| Kotani, Y; Kunimasa, K; Mimura, C | 1 |
| Corrao, G; Facchinetti, F; Ganzinelli, M; Garassino, MC; Lo Russo, G; Minari, R; Proto, C; Tiseo, M | 1 |
| Asai, K; Hirata, K; Kawaguchi, T; Kimura, T; Kuwae, Y; Matsumoto, Y; Mitsuoka, S; Sawa, K; Suzumura, T; Watanabe, T; Yamamoto, N; Yoshimoto, N; Yoshimura, N | 1 |
| Cheng, Y; Chewaskulyong, B; Cho, BC; Cho, EK; Dechaphunkul, A; Gray, JE; Hodge, R; Imamura, F; Kurata, T; Lee, KH; Lee, SM; Marotti, M; Nogami, N; Ohe, Y; Okamoto, I; Planchard, D; Ramalingam, SS; Reungwetwattana, T; Rukazenkov, Y; Soria, JC; Su, WC; Vansteenkiste, J; Voon, PJ; Zhou, C | 1 |
| Akerley, W; Chalmers, A; Jensen, L | 1 |
| Benes, CH; Damon, LJ; Dardaei, L; Dastur, A; Dicecca, R; Engelman, JA; Farago, AF; Fintelmann, FJ; Friboulet, L; Gainor, JF; Greenberg, M; Held, MA; Kattermann, KE; Kodack, DP; Lee, D; Niederst, MJ; Parks, M; Piotrowska, Z; Riley, AK; Rizzo, C; Sequist, LV; Shaw, AT; von Flotow, F | 1 |
| Oshima, Y; Tanimoto, T; Tojo, A; Yuji, K | 1 |
| Girard, N | 1 |
| Groen, HJM; Guo, Y; Li, J; Ma, J; Wang, P; Wang, Z; Yang, K; Zhang, C; Zhao, J | 1 |
| Borics, A; Dömötör, O; Enyedy, ÉA; Keppler, BK; Kowol, CR; Pelivan, K | 1 |
| Li, Y; Liu, Y; Ou, Q; Shao, YW; Wang, X; Wu, X; Ying, J | 1 |
| Aguiar, PN; de Lima Lopes, G; Del Giglio, A; Haaland, B; Park, W; San Tan, P | 1 |
| Masuda, N; Nakahara, Y; Niwa, H; Sasaki, J | 1 |
| Alexandre, J; Allard, M; Arrondeau, J; Bellesoeur, A; Blanchet, B; Boudou-Rouquette, P; Chapron, J; Giraud, F; Goldwasser, F; Labat, L; Reis, R; Thomas-Schoemann, A; Vidal, M | 1 |
| Enomoto, N; Fujisawa, T; Furuhashi, K; Hozumi, H; Inui, N; Karayama, M; Nakamura, Y; Suda, T; Suzuki, Y; Tsuchiya, K; Yasui, H | 1 |
| Hove, J; Powell, SF; Wynja, E | 1 |
| Chinet, T; Dumenil, C; Giroux-Leprieur, E | 1 |
| Chen, LY; Chen, ZT; Liao, XY; Sun, JG; Xu, ZH; Zheng, LP | 1 |
| Jiang, Y; Li, Z; Wan, S; Wu, X; Yan, R; Zhang, J | 1 |
| Chao, YH; Chen, PJ; Hsiao, YP; Kang, YT; Ko, JL; Lue, KH; Pan, HH; Sheu, JN | 1 |
| Cai, H; Chen, S; Li, N; Liu, MB; Weng, L; Yang, J; Zhang, L; Zheng, B | 1 |
| Carnero, A; Cirauqui, C; Conde, E; Enguita, AB; Ferrer, I; Marrugal, Á; Molina-Pinelo, S; Ojeda-Márquez, L; Paz-Ares, L; Ponce-Aix, S; Quintanal-Villalonga, A; Suarez, R | 1 |
| Iwami, E; Kuroda, A; Matsuzaki, T; Nakajima, T; Sasahara, K; Terashima, T | 1 |
| Ali, SM; Atkinson, EC; Chachoua, A; Nelson, AW; Pavlick, DC; Schrock, AB | 1 |
| Ding, JY; Gao, J; Jiang, JH; Jin, C; Li, HR | 1 |
| Wang, Z; Wu, YL | 1 |
| Ashtekar, K; DeVeaux, M; Gettinger, S; Goldberg, SB; Lemmon, MA; Lu, D; Park, JH; Politi, K; Song, X; Starrett, JH; Stewart, T; Truini, A; Walther, Z; Wurtz, A; Zelterman, D | 1 |
| Atagi, S; Hirashima, T; Imamura, F; Inoue, T; Kimura, M; Kuhara, H; Kumagai, T; Kunimasa, K; Moriizumi, K; Nakahama, K; Nishino, K; Suzuki, H; Tamiya, A; Tamiya, M; Taniguchi, Y | 1 |
| Costa, DB; Jänne, PA; Kobayashi, SS; Lau, CJ; Mushajiang, M; Oxnard, GR; Paweletz, CP; Rangachari, D; Shpilsky, JE; To, C; VanderLaan, PA | 1 |
| Bolan, PO; Brenan, L; Dusaj, N; Goodale, A; Johannessen, CM; Landau, DA; Piccioni, F; Schiffman, JS; Zviran, A | 1 |
| Cheema, P; Cheng, Y; Chewaskulyong, B; Cho, BC; Cobo, M; Gray, JE; Hodge, R; Imamura, F; John, T; Kurata, T; Lee, KH; Lin, MC; Ohe, Y; Planchard, D; Ramalingam, SS; Reungwetwattana, T; Rukazenkov, Y; Saggese, M; Shah, R; Soria, JC; Tiseo, M; Todd, A; Vansteenkiste, J; Zhou, C | 1 |
| An, Z; Fan, QW; Haas-Kogan, DA; Lu, M; Luo, X; Phillips, JJ; Shokat, KM; Weiss, WA; Wong, RA | 1 |
| Li, Y; Owonikoko, TK; Qian, G; Ramalingam, SR; Sun, SY; Zang, H | 1 |
| Cho, BC; Gray, JE; Hovey, T; Karaseva, N; Leighl, NB; Nakagawa, K; Novello, S; Rydén, A; Walding, A | 1 |
| Chen, H; Huang, J; Luo, Z; Meng, L; Sun, S; Yang, B | 1 |
| Abe, T; Asada, K; Hataji, O; Hayai, S; Hida, T; Imaizumi, K; Inui, N; Ito, K; Karayama, M; Kimura, T; Kubo, A; Kunii, E; Morikawa, S; Murotani, K; Okuno, M; Oya, Y; Shindoh, J; Suda, T; Takahashi, K; Taniguchi, H; Tsuda, T; Yamagichi, T; Yoshida, T | 1 |
| Endo, T; Funayama, Y; Furukawa, K; Hayashi, S; Hayashihara, K; Hizawa, N; Ichimura, H; Iguchi, K; Inagaki, M; Inage, Y; Ishikawa, H; Kaburagi, T; Kamiyama, K; Kikuchi, N; Kiyoshima, M; Kodama, T; Kurishima, K; Miyazaki, K; Nakamura, H; Nakamura, R; Nomura, A; Okubo, H; Saito, K; Saito, T; Sakai, M; Sato, Y; Satoh, H; Sekine, I; Shiozawa, T; Suzuki, H; Tamura, T; Yamada, H; Yamada, Y; Yamamoto, Y; Yamashita, T | 1 |
| Mohty, R; Tfayli, A | 1 |
| Ji, YX; Sun, L; Wang, SP; Zhao, ZM | 1 |
| Ando, C; Hara, N; Higo, H; Hirabae, A; Hotta, K; Ichihara, E; Kano, H; Kato, Y; Kayatani, H; Kiura, K; Kubo, T; Maeda, Y; Makimoto, G; Nakasuka, T; Ninomiya, K; Ninomiya, T; Nishii, K; Ohashi, K; Okawa, S; Rai, K; Tabata, M; Watanabe, H | 1 |
| Gupta, A; Momi, G; Vaid, AK | 1 |
| Chai, J; Cui, JW; Li, LY; Li, WQ | 1 |
| Hou, E; Lai, L; Lu, Y; Meng, W; Tan, Z; Wei, J; Zhang, X | 1 |
| Fujita, A; Hatsuyama, T; Inotsume, N; Mukai, Y; Sato, H; Toda, T; Wakamoto, A; Yoshida, T | 1 |
| Gursoy, P | 1 |
| Atagi, S; Daga, H; Izumi, M; Kaneda, H; Kawaguchi, T; Matsumoto, Y; Mitsuoka, S; Nakahama, K; Nakatani, Y; Ogawa, K; Okada, A; Okishio, K; Sawa, K; Tani, Y | 1 |
| Hirokawa, E; Nakagawa, K; Nishio, K; Sakai, K; Sato, C; Takahama, T; Takeda, M; Watanabe, S | 1 |
| Esposito, M; Glassman, L; Hannon, GJ; Huang, J; Hyman, K; Ibarra, I; Jimenez Sabinina, V; Korimerla, N; Lee, P; Lindsted, T; Lujambio, A; Miller, M; Pal, D; Safaric Tepes, P; Senturk, S; Sordella, R; Zeltsman, D | 1 |
| Akrour, Y; Duchemann, B; Gaudry, S; Gibelin, A; Gonzalez, F; Jaubert, P; Moreau, AS; Oppenheimer, A; Stoclin, A; Tandjaoui-Lambiotte, Y | 1 |
| Feng, J; Jiang, C; Li, H; Lin, Y; Qian, X; Xie, Y; Yin, Z; Yu, T; Zheng, S | 1 |
| Chang, HC; Chang, YP; Huang, KT; Lai, CH; Lin, MC; Tseng, CC; Wang, CC | 1 |
| Endo, M; Harada, H; Kenmotsu, H; Ko, R; Kobayashi, H; Kodama, H; Mamesaya, N; Miyawaki, E; Miyawaki, T; Mori, K; Murakami, H; Naito, T; Nishioka, N; Omori, S; Ono, A; Takahashi, K; Takahashi, T; Wakuda, K | 1 |
| Li, M; Luo, N; Qi, Y; Wang, M; Zhu, F | 1 |
| Azuma, K; Haratake, N; Hayashi, H; Nakagawa, K; Nakano, Y; Oki, M; Ota, K; Sakamoto, T; Seto, T; Shimokawa, M; Yamamoto, N; Yoshioka, H | 1 |
| Kagohashi, K; Satoh, H | 1 |
| Du, X; Liu, W; Wang, Z; Xiong, X; Yang, L; Yang, P; Zhang, Y; Zhou, C | 1 |
| Dhandha, S; Jaipuria, J; Khatri, M; Mattoo, S; Suryavanshi, M | 1 |
| Boily, G; Boulanger, J; Golo, KT; Guédon, AC; Lehuédé, C; Qureshi, S; Roussafi, F; Strumpf, E; Truchon, C | 1 |
| Chen, GY; Chen, KY; Liang, SK; Wei, YF; Weng, TI | 1 |
| Chen, HZ; Gong, M; Jiang, LL; Lei, HM; Liang, Q; Luo, MY; Shen, NX; Shen, Y; Wang, C; Xu, L; Zhang, KR; Zhang, MC; Zhang, R; Zhou, L; Zhu, L; Zhuang, G; Zou, JH | 1 |
| Boily, G; Boulanger, J; Pagé, É; Qureshi, S; Strumpf, E | 1 |
| Hanawa, T; Hyuga, S; Mori, E; Naoki, K; Odaguchi, H | 1 |
| Costa, DB; Kobayashi, IS; Kobayashi, SS; Lee, MD; Rangachari, D; Sentana-Lledo, D; Shaffer, W; Sundararaman, S; VanderLaan, PA | 1 |
| Chang, HC; Chang, YP; Chen, YC; Chen, YM; Chuang, HY; Huang, KT; Lai, CH; Tseng, CC; Wang, CC | 1 |
| Alahdab, A; Cinatl, J; Gohlke, L; Holdenrieder, S; Michaelis, M; Oberhofer, A; Ritter, CA; Worf, K | 1 |
7 review(s) available for erlotinib hydrochloride and osimertinib
| Article | Year |
|---|---|
Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer.
Topics: Acrylamides; Afatinib; Aniline Compounds; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Protein Kinase Inhibitors; Pyrimidines; Quinazolines | 2015 |
Epidermal Growth Factor Receptor Mutated Advanced Non-Small Cell Lung Cancer: A Changing Treatment Paradigm.
Topics: Acrylamides; Adenocarcinoma; Afatinib; Amino Acid Substitution; Aniline Compounds; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation, Missense; Piperazines; Protein Kinase Inhibitors; Quinazolines | 2017 |
Treatment in EGFR-mutated non-small cell lung cancer: how to block the receptor and overcome resistance mechanisms.
Topics: Acrylamides; Afatinib; Aniline Compounds; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Mutation; Piperazines; Protein Kinase Inhibitors; Quinazolines | 2017 |
Optimizing outcomes in EGFR mutation-positive NSCLC: which tyrosine kinase inhibitor and when?
Topics: Acrylamides; Afatinib; Aniline Compounds; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Mutation; Piperazines; Protein Kinase Inhibitors; Quinazolines | 2018 |
Strategies to overcome acquired resistance to EGFR TKI in the treatment of non-small cell lung cancer.
Topics: Acrylamides; Afatinib; Aniline Compounds; Antineoplastic Agents; Axl Receptor Tyrosine Kinase; Carcinoma, Non-Small-Cell Lung; Cell Transformation, Neoplastic; Class I Phosphatidylinositol 3-Kinases; Disease Progression; Drug Resistance, Neoplasm; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Immunotherapy; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-met; Quinazolinones; Receptor Protein-Tyrosine Kinases; Receptor, IGF Type 1; Signal Transduction | 2019 |
Overall survival in stage IV EGFR mutation‑positive NSCLC: Comparing first‑, second‑ and third‑generation EGFR‑TKIs (Review).
Topics: Acrylamides; Administration, Oral; Afatinib; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Neoplasm Staging; Progression-Free Survival; Protein Kinase Inhibitors; Quinazolinones; Randomized Controlled Trials as Topic | 2021 |
Survival outcomes of east Asian patients with advanced non-small cell lung cancer treated with first-line EGFR tyrosine kinase inhibitors: A network meta-analysis of real-world evidence.
Topics: Adult; Afatinib; Carcinoma, Non-Small-Cell Lung; East Asian People; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Network Meta-Analysis; Protein Kinase Inhibitors; Tyrosine Kinase Inhibitors | 2023 |
6 trial(s) available for erlotinib hydrochloride and osimertinib
| Article | Year |
|---|---|
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
Topics: Acrylamides; Adult; Aged; Aged, 80 and over; Aniline Compounds; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Double-Blind Method; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Survival Rate | 2018 |
Cost-effectiveness of Osimertinib in the First-Line Treatment of Patients With EGFR-Mutated Advanced Non-Small Cell Lung Cancer.
Topics: Acrylamides; Afatinib; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Brazil; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; ErbB Receptors; Erlotinib Hydrochloride; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Mutation; Prognosis; United States | 2018 |
Overall Survival with Osimertinib in Untreated,
Topics: Acrylamides; Aged; Aniline Compounds; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Double-Blind Method; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Proportional Hazards Models; Protein Kinase Inhibitors | 2020 |
Treatment of Patients With Non-small-cell Lung Cancer With Uncommon
Topics: Acrylamides; Adult; Afatinib; Aged; Aged, 80 and over; Aniline Compounds; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Male; Middle Aged; Mutation; Progression-Free Survival; Protein Kinase Inhibitors | 2020 |
Phase 1b study of ramucirumab in combination with erlotinib or osimertinib for untreated EGFR-mutated non-small cell lung cancer patients with asymptomatic brain metastases.
Topics: Acrylamides; Aged; Aniline Compounds; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Ramucirumab | 2021 |
Phase III Clinical Trial for the Combination of Erlotinib Plus Ramucirumab Compared With Osimertinib in Previously Untreated Advanced or Recurrent Non-Small Cell Lung Cancer Positive for the L858R Mutation of EGFR: REVOL858R (WJOG14420L).
Topics: Acrylamides; Aniline Compounds; Antibodies, Monoclonal, Humanized; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Genes, erbB-1; Humans; Lung Neoplasms; Mutation; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Ramucirumab | 2022 |
58 other study(ies) available for erlotinib hydrochloride and osimertinib
| Article | Year |
|---|---|
Binding mode of the breakthrough inhibitor AZD9291 to epidermal growth factor receptor revealed.
Topics: Acrylamides; Aniline Compounds; Antineoplastic Agents; Crystallography, X-Ray; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Binding; Protein Kinase Inhibitors; Quinazolines | 2015 |
4-Aminoindazolyl-dihydrofuro[3,4-d]pyrimidines as non-covalent inhibitors of mutant epidermal growth factor receptor tyrosine kinase.
Topics: Acrylamides; Aniline Compounds; Animals; Binding Sites; Crystallography, X-Ray; Dogs; ErbB Receptors; Erlotinib Hydrochloride; Furans; Hepatocytes; High-Throughput Screening Assays; Humans; Hydrogen Bonding; Indazoles; Mice; Microsomes, Liver; Point Mutation; Protein Kinase Inhibitors; Pyrimidines; Rats | 2016 |
Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment.
Topics: Acrylamides; Aniline Compounds; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Crizotinib; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; G1 Phase Cell Cycle Checkpoints; Gene Amplification; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mice, Nude; Molecular Targeted Therapy; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; Pyrimidines; RNA Interference; Signal Transduction; Time Factors; Transfection; Tumor Burden; Xenograft Model Antitumor Assays | 2016 |
EGFR L858M/L861Q cis Mutations Confer Selective Sensitivity to Afatinib.
Topics: Acrylamides; Adenocarcinoma; Afatinib; Alleles; Aniline Compounds; Animals; Antineoplastic Agents; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Mice; Middle Aged; NIH 3T3 Cells; Phosphorylation; Piperazines; Point Mutation; Protein Kinase Inhibitors; Quinazolines; Tumor Cells, Cultured | 2017 |
Erlotinib Is Effective for Leptomeningeal Carcinomatosis due to Disease Flare after Osimertinib Treatment Failure.
Topics: Acrylamides; Aniline Compounds; Antineoplastic Agents; Erlotinib Hydrochloride; Female; Humans; Meningeal Carcinomatosis; Middle Aged; Piperazines; Treatment Failure | 2017 |
Interstitial Lung Disease Induced by Osimertinib for Epidermal Growth Factor Receptor (EGFR) T790M-positive Non-small Cell Lung Cancer.
Topics: Acrylamides; Adenocarcinoma; Adenocarcinoma of Lung; Aged; Aniline Compounds; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Neoplasm Recurrence, Local; Piperazines; Protein Kinase Inhibitors | 2017 |
Durable response to osimertinib in EGFR mutated T790M wildtype non-small cell lung cancer with leptomeningeal metastases: A case report.
Topics: Acrylamides; Aged; Aniline Compounds; Brain; Carcinoma, Non-Small-Cell Lung; Cerebrospinal Fluid; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Meningeal Neoplasms; Mutation; Piperazines; Protein Kinase Inhibitors | 2017 |
Primary Patient-Derived Cancer Cells and Their Potential for Personalized Cancer Patient Care.
Topics: Acrylamides; Aminopyridines; Anaplastic Lymphoma Kinase; Aniline Compounds; Antineoplastic Agents; Biomarkers, Tumor; Biopsy; Crizotinib; ErbB Receptors; Erlotinib Hydrochloride; Feeder Cells; Fluorescent Antibody Technique; Gene Expression; High-Throughput Screening Assays; Humans; Keratin-18; Keratin-8; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Mutation; Neoplasms; Piperazines; Precision Medicine; Primary Cell Culture; Pyrazoles; Pyridines; Receptor Protein-Tyrosine Kinases; Tumor Cells, Cultured | 2017 |
EGFR-TKI-Associated Interstitial Pneumonitis in Nivolumab-Treated Patients With Non-Small Cell Lung Cancer.
Topics: Acrylamides; Afatinib; Aged; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Databases, Factual; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Mutation; Nivolumab; Prognosis | 2018 |
Uncommon EGFR G724S mutations arise in non-small-cell lung cancer patients with acquired resistance to first-generation EGFR-TKIs.
Topics: Acrylamides; Aniline Compounds; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genetic Testing; Humans; Lung Neoplasms; Mutation; Piperazines; Protein Kinase Inhibitors; Treatment Outcome | 2018 |
Comparative studies on the human serum albumin binding of the clinically approved EGFR inhibitors gefitinib, erlotinib, afatinib, osimertinib and the investigational inhibitor KP2187.
Topics: Acrylamides; Afatinib; Aniline Compounds; Binding Sites; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Hydrogen Bonding; Molecular Docking Simulation; Piperazines; Protein Binding; Protein Kinase Inhibitors; Quinazolines; Serum Albumin, Human; Solvents; Spectrometry, Fluorescence | 2018 |
Acquired EGFR L718V mutation mediates resistance to osimertinib in non-small cell lung cancer but retains sensitivity to afatinib.
Topics: Acrylamides; Afatinib; Aged; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Carcinogenesis; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; High-Throughput Nucleotide Sequencing; Humans; Lung Neoplasms; Male; Mutation; Piperazines; Protein Kinase Inhibitors; Tumor Cells, Cultured | 2018 |
A promising response to osimertinib in a patient with erlotinib-resistant lung adenocarcinoma with an uncommon EGFR mutation.
Topics: Acrylamides; Adenocarcinoma; Adenocarcinoma of Lung; Aged; Aniline Compounds; Antineoplastic Agents; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Mutation; Piperazines; Positron Emission Tomography Computed Tomography; Tomography, X-Ray Computed; Treatment Outcome | 2018 |
Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the EGFR inhibitors afatinib, erlotinib and osimertinib, the ALK inhibitor crizotinib and the VEGFR inhibitor nintedanib in human plasma from non-small cell lung canc
Topics: Acrylamides; Afatinib; Aniline Compounds; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chromatography, High Pressure Liquid; Crizotinib; Drug Monitoring; Drug Stability; ErbB Receptors; Erlotinib Hydrochloride; Humans; Indoles; Limit of Detection; Lung Neoplasms; Piperazines; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry | 2018 |
An Acquired Epidermal Growth Factor Receptor T790M Mutation after the Addition of Bevacizumab to Preceding Erlotinib Monotherapy in a Lung Cancer Patient with Leptomeningeal Metastases.
Topics: Acrylamides; Adenocarcinoma of Lung; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; ErbB Receptors; Erlotinib Hydrochloride; Exons; Gene Deletion; Humans; Lung Neoplasms; Male; Meningeal Carcinomatosis; Middle Aged; Piperazines; Treatment Outcome | 2018 |
A Patient With EGFR-Mutated Lung Cancer Progressing on Erlotinib: Evaluating for a T790M Mutation With Limited Tissue.
Topics: Acrylamides; Adenocarcinoma of Lung; Aged; Aniline Compounds; Antineoplastic Agents; Cell-Free Nucleic Acids; Disease Progression; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Piperazines; Polymorphism, Restriction Fragment Length | 2018 |
Combination of Crizotinib and Osimertinib or Erlotinib Might Overcome MET-Mediated Resistance to EGFR Tyrosine Kinase Inhibitor in EGFR-Mutated Adenocarcinoma.
Topics: Acrylamides; Adenocarcinoma; Aged; Aniline Compounds; Crizotinib; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Protein Kinase Inhibitors | 2018 |
Case report: primary resistance to osimertinib in erlotinib-pretreated lung adenocarcinoma with EGFR T790 M mutation.
Topics: Acrylamides; Adenocarcinoma of Lung; Aniline Compounds; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Male; Middle Aged; Mutation; Piperazines; Protein Kinase Inhibitors; Tumor Suppressor Protein p53 | 2018 |
Insight into binding mechanisms of EGFR allosteric inhibitors using molecular dynamics simulations and free energy calculations.
Topics: Acrylamides; Allosteric Regulation; Aniline Compounds; Benzeneacetamides; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Molecular Dynamics Simulation; Mutation; Protein Binding; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2019 |
Epithelial growth factor receptor tyrosine kinase inhibitors alleviate house dust mite allergen Der p2-induced IL-6 and IL-8.
Topics: Acrylamides; Aniline Compounds; Animals; Antigens, Dermatophagoides; Arthropod Proteins; Asthma; Cell Line; Dermatophagoides pteronyssinus; Dose-Response Relationship, Drug; Epithelial Cells; ErbB Receptors; Erlotinib Hydrochloride; Humans; Interleukin-6; Interleukin-8; Respiratory Mucosa; Signal Transduction | 2019 |
Cost-effectiveness of Osimertinib as First-line Treatment and Sequential Therapy for EGFR Mutation-positive Non-small Cell Lung Cancer in China.
Topics: Acrylamides; Aniline Compounds; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; China; Cost-Benefit Analysis; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors | 2019 |
FGFR1 Cooperates with EGFR in Lung Cancer Oncogenesis, and Their Combined Inhibition Shows Improved Efficacy.
Topics: Acrylamides; Aniline Compounds; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Carcinogenesis; Cell Line, Tumor; Drug Synergism; Enzyme Activation; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Receptor, Fibroblast Growth Factor, Type 1; Transfection; Xenograft Model Antitumor Assays | 2019 |
A case report of metastatic lung adenocarcinoma with long-term survival for over 11 years.
Topics: Acrylamides; Aged; Aniline Compounds; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Piperazines; Protein Kinase Inhibitors | 2019 |
Novel SPECC1L-MET Fusion Detected in Circulating Tumor DNA in a Patient with Lung Adenocarcinoma following Treatment with Erlotinib and Osimertinib.
Topics: Acrylamides; Adenocarcinoma; Aged, 80 and over; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Crizotinib; Disease Progression; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Humans; Lung Neoplasms; Male; Oncogene Fusion; Phosphoproteins; Proto-Oncogene Proteins c-met | 2019 |
Re-emerging C797S In Trans and Rechallenge of Osimertinib With Erlotinib.
Topics: Acrylamides; Adenocarcinoma of Lung; Aniline Compounds; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors | 2019 |
The EGFR Exon 19 Mutant L747-A750>P Exhibits Distinct Sensitivity to Tyrosine Kinase Inhibitors in Lung Adenocarcinoma.
Topics: Acrylamides; Adenocarcinoma of Lung; Afatinib; Aniline Compounds; Animals; CHO Cells; Cricetulus; ErbB Receptors; Erlotinib Hydrochloride; Exons; Gene Deletion; Humans; Models, Chemical; Molecular Dynamics Simulation; Mutation; Protein Kinase Inhibitors; Treatment Outcome | 2019 |
Which Is Better EGFR-TKI Followed by Osimertinib: Afatinib or Gefitinib/Erlotinib?
Topics: Acrylamides; Adult; Afatinib; Aged; Aged, 80 and over; Aniline Compounds; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Treatment Outcome | 2019 |
EGFR-Mutated Lung Cancers Resistant to Osimertinib through EGFR C797S Respond to First-Generation Reversible EGFR Inhibitors but Eventually Acquire EGFR T790M/C797S in Preclinical Models and Clinical Samples.
Topics: Acrylamides; Alkylating Agents; Aniline Compounds; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cells, Cultured; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Ethylnitrosourea; Female; Gefitinib; Humans; Lung Neoplasms; Mice; Middle Aged; Mutagenesis; Mutation; Precursor Cells, B-Lymphoid; Protein Kinase Inhibitors; Retrospective Studies; Treatment Outcome | 2019 |
Genotype-Fitness Maps of EGFR-Mutant Lung Adenocarcinoma Chart the Evolutionary Landscape of Resistance for Combination Therapy Optimization.
Topics: Acrylamides; Adenocarcinoma of Lung; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Genetic Fitness; Genotype; Humans; Lung Neoplasms; MAP Kinase Signaling System; Mutation | 2020 |
Cooperative Blockade of PKCα and JAK2 Drives Apoptosis in Glioblastoma.
Topics: Acrylamides; Aniline Compounds; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Brain Neoplasms; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Female; Glioblastoma; Humans; Indoles; Janus Kinase 2; Mice; Morpholines; Protein Kinase C-alpha; Protein Kinase Inhibitors; Purines; Pyrazoles; Pyrimidines; Signal Transduction; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2020 |
ERK inhibition effectively overcomes acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib.
Topics: Acrylamides; Afatinib; Aniline Compounds; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; MAP Kinase Signaling System; Mice; Mice, Nude; Mutation; Myeloid Cell Leukemia Sequence 1 Protein; Neoplastic Stem Cells; Protein Kinase Inhibitors; Pyridones; Pyrimidinones; Xenograft Model Antitumor Assays | 2020 |
Patient-reported outcomes from FLAURA: Osimertinib versus erlotinib or gefitinib in patients with EGFR-mutated advanced non-small-cell lung cancer.
Topics: Acrylamides; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Patient Reported Outcome Measures | 2020 |
Safety Profile of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Disproportionality Analysis of FDA Adverse Event Reporting System.
Topics: Acrylamides; Adverse Drug Reaction Reporting Systems; Afatinib; Aniline Compounds; Data Mining; Databases, Factual; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Pharmacovigilance; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Safety; United States; United States Food and Drug Administration | 2020 |
Propensity score analysis of overall survival between first- and second-generation EGFR-TKIs using real-world data.
Topics: Acrylamides; Adult; Afatinib; Aged; Aged, 80 and over; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Japan; Male; Middle Aged; Mutation; Protein Kinase Inhibitors | 2020 |
EGFR tyrosine kinase inhibitors in non-small cell lung cancer: treatment paradigm, current evidence, and challenges.
Topics: Acrylamides; Afatinib; Aniline Compounds; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolinones | 2021 |
Crizotinib plus erlotinib overcomes osimertinib resistance in a seriously-ill non-small cell lung cancer patient with acquired MET amplification.
Topics: Acrylamides; Aniline Compounds; Carcinoma, Non-Small-Cell Lung; Crizotinib; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met | 2020 |
VEGFR2 blockade augments the effects of tyrosine kinase inhibitors by inhibiting angiogenesis and oncogenic signaling in oncogene-driven non-small-cell lung cancers.
Topics: A549 Cells; Acrylamides; Anaplastic Lymphoma Kinase; Angiogenesis Inhibitors; Aniline Compounds; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carbazoles; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Combined Modality Therapy; Crizotinib; Drug Synergism; Erlotinib Hydrochloride; Female; Genes, erbB-1; Heterografts; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Targeted Therapy; Mutation; Neovascularization, Pathologic; Oncogenes; Piperidines; Platelet Endothelial Cell Adhesion Molecule-1; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Ramucirumab; Random Allocation; Signal Transduction; Vascular Endothelial Growth Factor Receptor-2 | 2021 |
Cost-effectiveness analysis of first-line treatments for advanced epidermal growth factor receptor-mutant non-small cell lung cancer patients.
Topics: Acrylamides; Angiogenesis Inhibitors; Aniline Compounds; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; China; Clinical Trials as Topic; Cost-Benefit Analysis; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Markov Chains; Mutation; Protein Kinase Inhibitors; Quality-Adjusted Life Years; Quinazolinones | 2021 |
Transformation of NSCLC to SCLC after 1st- and 3rd-generation EGFR-TKI resistance and response to EP regimen and erlotinib: 2 CARE-compliant case reports.
Topics: Acrylamides; Adult; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Resistance, Neoplasm; Epirubicin; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Female; Humans; Lung; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Pneumonectomy; Protein Kinase Inhibitors; Small Cell Lung Carcinoma; Tomography, X-Ray Computed; Treatment Outcome | 2021 |
An Liquid Chromatography-Tandem Mass Spectrometry Method for the Simultaneous Determination of Afatinib, Alectinib, Ceritinib, Crizotinib, Dacomitinib, Erlotinib, Gefitinib, and Osimertinib in Human Serum.
Topics: Acrylamides; Afatinib; Aniline Compounds; Carbazoles; Chromatography, Liquid; Crizotinib; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Quinazolinones; Sulfones; Tandem Mass Spectrometry | 2021 |
Re-use of erlotinib in a patient using osimertinib after erlotinib, case report.
Topics: Acrylamides; Aged; Aniline Compounds; Carcinoma, Non-Small-Cell Lung; Drug Substitution; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors | 2022 |
Durable response to EGFR tyrosine kinase inhibitors in a patient with non-small cell lung cancer harboring an EGFR kinase domain duplication.
Topics: Acrylamides; Aniline Compounds; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Duplication; Humans; Lung Neoplasms; Meningeal Carcinomatosis; Middle Aged; Protein Kinase Inhibitors | 2021 |
An epigenetic switch regulates the ontogeny of AXL-positive/EGFR-TKi-resistant cells by modulating miR-335 expression.
Topics: Acrylamides; Aniline Compounds; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Epigenesis, Genetic; ErbB Receptors; Erlotinib Hydrochloride; Humans; Intercellular Signaling Peptides and Proteins; Lung Neoplasms; MicroRNAs; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases; RNA, Messenger | 2021 |
Tyrosine Kinase Inhibitors for Acute Respiratory Failure Because of Non-small-Cell Lung Cancer Involvement in the ICU.
Topics: Acrylamides; Adenocarcinoma of Lung; Adult; Aged; Aniline Compounds; Carcinoma, Non-Small-Cell Lung; Crizotinib; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Intensive Care Units; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Noninvasive Ventilation; Oxygen Inhalation Therapy; Protein Kinase Inhibitors; Respiration, Artificial; Respiratory Insufficiency; Retrospective Studies; Survival Rate | 2022 |
Complete remission in leptomeningeal metastasis of NSCLC with rare EGFR-SEPT14 fusion treated with osimertinib combined with intrathecal chemotherapy with pemetrexed.
Topics: Acrylamides; Aniline Compounds; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gene Fusion; High-Throughput Nucleotide Sequencing; Humans; Injections, Spinal; Lung Neoplasms; Male; Meningeal Neoplasms; Middle Aged; Neoplasm Metastasis; Pemetrexed; Septins | 2022 |
Comparing survival and treatment response of patients with acquired T790M mutation second-line osimertinib versus sequential treatment of chemotherapy followed by osimertinib: A real-world study.
Topics: Acrylamides; Adenocarcinoma of Lung; Adult; Afatinib; Aged; Aged, 80 and over; Aniline Compounds; Drug Therapy; Erlotinib Hydrochloride; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Progression-Free Survival; Protein Kinase Inhibitors; Retrospective Studies | 2021 |
Association between oligo-residual disease and patterns of failure during EGFR-TKI treatment in EGFR-mutated non-small cell lung cancer: a retrospective study.
Topics: Acrylamides; Adenocarcinoma; Adult; Afatinib; Aged; Aged, 80 and over; Aniline Compounds; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genes, erbB-1; Humans; Logistic Models; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm, Residual; Protein Kinase Inhibitors; Retrospective Studies; Time Factors; Treatment Failure | 2021 |
Erlotinib combined with bevacizumab and chemotherapy in first line osimertinib-resistant NSCLC patient with leptomeningeal metastasis: A case report.
Topics: Acrylamides; Aniline Compounds; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Circulating Tumor DNA; Cisplatin; ErbB Receptors; Erlotinib Hydrochloride; Female; Genes, erbB-1; High-Throughput Nucleotide Sequencing; Humans; Lung Neoplasms; Meningeal Carcinomatosis; Middle Aged; Mutation; Pemetrexed; Protein Kinase Inhibitors | 2021 |
Response to erlotinib and bevacizumab combination therapy after acquired resistance to osimertinib in patients with non-small cell lung cancer.
Topics: Acrylamides; Aniline Compounds; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors | 2022 |
Simultaneous quantitative detection of afatinib, erlotinib, gefitinib, icotinib, osimertinib and their metabolites in plasma samples of patients with non-small cell lung cancer using liquid chromatography-tandem mass spectrometry.
Topics: Acrylamides; Afatinib; Aniline Compounds; Carcinoma, Non-Small-Cell Lung; Chromatography, Liquid; Crown Ethers; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Reproducibility of Results; Tandem Mass Spectrometry | 2022 |
Audit of Molecular Mechanisms of Primary and Secondary Resistance to Various Generations of Tyrosine Kinase Inhibitors in Known Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Cancer Patients in a Tertiary Centre.
Topics: Acrylamides; Afatinib; Aniline Compounds; Carcinoma, Non-Small-Cell Lung; Class I Phosphatidylinositol 3-Kinases; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Genes, erbB-1; Humans; Indoles; Lung Neoplasms; Mutation; Nucleic Acids; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Pyrimidines; Retrospective Studies | 2022 |
Advanced Lung Cancer Patients' Use of EGFR Tyrosine Kinase Inhibitors and Overall Survival: Real-World Evidence from Quebec, Canada.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quebec | 2022 |
Determining plasma and cerebrospinal fluid concentrations of EGFR-TKI in lung cancer patients.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; Chromatography, Liquid; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Tandem Mass Spectrometry | 2023 |
A phosphoglycerate mutase 1 allosteric inhibitor overcomes drug resistance to EGFR-targeted therapy via disrupting IL-6/JAK2/STAT3 signaling pathway in lung adenocarcinoma.
Topics: Adenocarcinoma of Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Interleukin-6; Janus Kinase 2; Lung Neoplasms; Mutation; Phosphoglycerate Mutase; Protein Kinase Inhibitors; Signal Transduction | 2023 |
Inequalities in survival and care across social determinants of health in a cohort of advanced lung cancer patients in Quebec (Canada): A high-resolution population-level analysis.
Topics: Canada; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quebec; Social Determinants of Health | 2023 |
Effects of Ephedra Herb extract on the expression of EGFR-activating mutations and c-Met in non-small-cell lung cancer cell line, H1975, and its combined effects with osimertinib.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors | 2023 |
EGFR exon 19 insertion EGFR-K745_E746insIPVAIK and others with rare XPVAIK amino-acid insertions: Preclinical and clinical characterization of the favorable therapeutic window to all classes of approved EGFR kinase inhibitors.
Topics: Afatinib; Amino Acids; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Exons; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors | 2023 |
Loss of Key EMT-Regulating miRNAs Highlight the Role of ZEB1 in EGFR Tyrosine Kinase Inhibitor-Resistant NSCLC.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; MicroRNAs; Mutation; Protein Kinase Inhibitors; Tyrosine Kinase Inhibitors; Zinc Finger E-box-Binding Homeobox 1 | 2023 |